The RFLP/PCR approach (restriction fragment length polymorphism/polymerase chain reaction) to genotypic mutation analysis described here 
INTRODUCTION
Molecular characterization and quantitation of mutations is of fundamental importance to the understanding of evolution, differentiation and the etiology of hereditary disease. The frequent occurrence of single base pair changes in the activation of the ras protooncogenes (1) and in the inactivation of the tumor suppressor gene p53 (2) (3) (4) documents the involvement of mutations in human carcinogenesis. Ideally, methods are required which allow it to identify specific DNA sequence changes in relevant genes in tissue biopsies. For the elucidation of early pathogenetic processes it is necessary to detect these changes in a minute minority of cells without the clonal expansion of mutated cells in vivo or in vitro and without the need for the expression of a selectable mutant phenotype (5) . To achieve this goal it is necessary to isolate specific mutated DNA sequences from a large excess of homologous wild type DNA by biochemical means. In contrast, all classical 'phenotypic' mutation systems rely on the isolation of a few mutated cells from a large, usually dividing cell population. This limits mutation analysis to a few genes encoding proteins which produce a selectable cellular phenotype.
A number of experimental approaches to 'genotypic' mutation systems have been developed (6) . Several are based on Southernor Northern hybridization often with sequence amplification by polymerase chain reaction (PCR) and in combination with the specific cleavage of hetero-duplexes at mismatched base pairs. Other protocols take advantage of differences in electrophoretic mobilities of hetero-duplexes or of mutated single stranded nucleic acids. The sensitivity of all these approaches are limited by backgrounds which arise from the presence of excess wild-type sequences. The RFLP/PCR approach to genotypic mutation analysis described here greatly reduces this problem. Base-pair (bp) mutations are detected which are located in a restriction recognition sequence and render this site resistant to cleavage by the corresponding endonuclease. The resistant DNA sequence containing the mutated site is amplified by PCR only after wild tpe DNA has been essentially eliminated by restriction digestion. Amplified DNA is cloned into XgtlO and mutants are quantitated by oligonucleotide plaque hybridization relative to an internal standard. The maximal sensitivity of the RFLP/PCR method is determined by the completeness of the removal of wild-type sequences together with the inherent error-rate at a particular base pair of the polymerase used in the PCR. The RFLP/PCR protocol for genotypic mutation analysis is applicable to any gene of known sequence. It is highly sensitive, but limited to the identification of point mutations (bp-changes, small deletions and insertions) * To whom correspondence should be addressed + Present address: Toxicology Department-ZYMA SA-1260 Nyon, Switzerland which result in the elimination of restriction sites. We report here results involving bp-changes in the PvuII site 1727-1732 and the MspI site 1695 -1698 of exon 1 of the human c-Ha-rasl gene. The MspI-site 1695-1698 covers 2 bp of codon 12 of c-ras which represents a mutation hot spot in human cancer (1) .
METHODS
RFLP/PCR analysis of PvuII-site 1727-1732 of c-Ha-rasl Preparation of authentic mutants at PvuII-site 1727-1732 of cHa-ras]. All 12 possible single bp mutations in the internal tetranucleotide AGCT of the Pvull recognition sequence (residues 1727-1732) of exon 1 of the human c-Ha-rasl gene were prepared using synthetic oligonuleotides and a PCR protocol (see Figure 1 for sequence information). Twelve different 20-mers corresponding to residues 1719-1738 which contained single base changes in the AGCT sequence were used as left-side amplimers. A common right-side amplimer corresponding to nucleotides 1765-1784 of c-Ha-rasl plus a 12 nucleotide tail containing an EcoRI recognition-sequence was used in 12 PCR reactions with pSVneo-rasl as template (note: pSVneo-ras 1 contains the BamHI fragment, residues 1-6453, of human cHa-rasl (7) inserted into the BamHI sites of the SVneo cloning vector). The amplification conditions were as described below. The 12 resulting 78 bp fragments were purified on Quiagen-5 tips as described by the supplier (DIAGEN, KONTRON, Switzerland) and then used as right-side amplimers in a second round of amplifications with a common left-side amplimer corresponding to residues 1646-1665 of c-Ha-rasl plus a 12 nucleotide tail containing an EcoRI recognition sequence. The resulting 163 bp fragments were purified on Quiagen-5 tips, digested with EcoRI and cloned into XgtlO.
All authentic mutant XgtlO constructs were plaque purified on E. coli C600 Hfl. For this purpose plaques were lifted onto colony/plaque screens and probed with mutant specific 32P-endlabeled oligonucleotides. Positive plaques were picked, the phage eluted from the agar and plated onto E. coli C600 Hfl. When confluent lysis had been achieved the phage was collected in Sml buffer (1OOmM NaCl, 20 mM Tris.HCl pH 7.4, lOmM MgSO4) and after the addition of 100 Al CHCl3 the suspension was centrifuged at 10'000 rpm for 10 min at 4°C. Mutant phage contained in the supernatant was titered and then stored at 4°C in the presence of 0.3% CHCl3.
A mutant standard with two bp changes in the Pvull recognition sequence and an additional upstream mutation was prepared according to the same experimental design using the 20-mer 5'T-GAGCATCCTGGTGATCCAG (residues 1719-1738 of c-HarasI; positions of mutations underlined) as left-side amplimer and a 20-mer corresponding to the sequence from residue 1888 to 1907 of c-Ha-rasl as right-side amplimer. The right-side amplimer contains a XbaI recognition site. The amplification conditions were as described below except that the DMSO concentration was only 6%. After 38 cycles the resulting 188 bp fragment was purified on a Quiagen-5 tip and used as rightside amplimer in a second amplification reaction with a left-side amplimer corresponding to residues 1636 to 1655 of c-Ha-rasl which contains a SmaI site. After purification the final 272 bp fragment was digested with XbaI and SmaI and cloned into pSP64. This plasmid, referred to as 'mutant standard' (pSP64-ras PvuIISt), was used as internal standard in mixtures with pSVneo-ras 1. (9) . This vector, referred to below as pSP64-rasl-T1698 was used in the mutant rescue experiments described below.
MspI/HpaII-restriction and amplification. Stocks ofpSVneo-rasl were digested exhaustively with lOU MspI/Lg and 2U Hpall/ug plasmid overnight at 370 under the conditions described above for Pvul. pSP64-rasl-T1698 was digested with XbaI-EcoRI in order to release a 261 bp fragment containing the mutated MspIsite 1695-1698 CCGT. Three samples were prepared in the amplification buffer described above except that the DMSO concentration was only 6%: a) 108 copies restricted pSVneorasl b) 100 copies restricted pSP64-rasl-T1698 plus 108 copies restricted pSVneo-rasl c) 1000 copies restricted pSP64-rasl-T1698 plus 108 copies restricted pSVneo-rasl. The amplimers used in the first 35 PCR cycles were 20-mers corresponding to the sequences 1646-1665 and 1765-1784 of c-Ha-rasl (see Figure 1) . The Figure 2 . The upper portion shows that radiolabeled left-side amplimer (see Figure 1 for CACCTG occurring with moderate frequency (upper portion) and a C-G transversion giving rise to CAGGTG which represents a frequent Taq-induced mutation in the Pvull site (lower portion). In all cases the specificity of the probing conditions was ascertained with mixtures of authentic mutant constructs and by assuring that each plaque only hybridized with a single oligonucleotide probe. Figure 4 compares the frequencies of the 12 possible Taqpolymerase induced bp changes at the internal tetranucleotide A-GCT of the Pvul-site in 3 independent amplification experiments in which 109 ( Figure 4A ) and 108 initial copies of wt pSVneorasl ( Figure 4B & C) were used, respectively. While there are small quantitative differences the following consensus can be reached for the relative abundance of Taq-induced errors: C-A(AGAT) _ C-G(AGGT)>G-T(ATCT). Since the amount of wt-copies which remain undigested during the amplification cycles is not known absolute Taq-error frequencies cannot be derived from our data. In contrast, from a comparison to the data with the mutant standard it is evident that less than 10 copies containing a single bp mutation in the presence of 109 copies of wt-sequence can readily be detected for mutations with low Taq-error frequencies, e.g. for A-C(CGCT); T-G(A-GCG); T-A(AGCA); A-T(TGCT); G-A(AACT).
Rescue of a single base pair mutation in MspI-site 1695-1698 from excess wild-type c-Ha-rasl DNA The rescue of mutant standard such as pSP64-ras PvullSt with multiple bp changes in a chosen restriction site from excess wt sequences is not affected by Taq-polymerase errors. In contrast, the sensitivity of the detection of single bp mutations is limited by polymerase errors originating from the amplification of residual undigested wt sequences. We assessed the capacity of the RFLP/PCR protocol to rescue a few copies of the c-Ha-rasl exon 1 fragment 1646-1784 containing a G-T transversion at residue 1698 which is part of the MspI-site 1695-1698 from a large excess of wt c-Ha-rasl DNA. The chosen mutation affects the middle bp of codon 12 and was detected in the c-Ha-rasl gene of the EJ human bladder carcinoma line (8) (see Figure 1 for sequence information). Three samples were analyzed by RFLP/PCR (1) 108 copies of exhaustively MspI/HpalI digested wt pSVneo-rasl (2) 100 copies mutant pSP64-rasl-T1698 (XbaI/EcoRI restricted) plus 108 copies MspI/HpaII digested pSVneo-ras (3) 1000 copies mutant pSP64-rasl-T1698 (XbaI/EcoRI restricted) plus 108 copies MspI/HpaII digested pSVneo-rasl. The samples were amplified with repeated MspI restrictions in 35 cycles with 'non-clonable' amplimers and 10 final cycles with amplimers containing tails with EcoRI recognition sequences (see Figure 1 and Methods). The amplified 136 bp fragments were cloned into XgtlO and plaques analyzed by hybridization with 20-mer oligonucleotides corresponding to the wt c-Ha-rasl sequence 1688-1707 and with the mutant sequence containing a T-residue at position 1698. From the results shown in Figure 5 it is evident that Taq-polymerase amplification of residual wt ras I DNA which escaped restriction at the MspIsite 1695-1698 generated 12% X-plaques with G-T transversions at residue 1698 for the sample containing only 108 copies of pSVneo-rasl at the outset. The percentage of plaques containing G-T transversions at residue 1698 was 23 % for the initial mixture of 100 copies mutant pSP64-rasl-T1698 with 108 copies of wt pSVneo-rasl corresponding to a 2 fold increase over Figure 4 attests to the large differences in Taq-polymerase errors depending on the type of bp and the sequence. The replication of G.C bp produced more errors then the replication of A.T bp and transversions were considerably more frequent than transitions. Sequence dependence is indicated by the fact that the C -G transversion (AGGT) was more frequent than the G -C transversion (ACCT) and the C-A transversion (AGAT) more frequent than the G-T transversion (ATCT). Comparison of the three panels in Figure 4 indicates that the fraction of plaques with Taq The predominance of transversions involving G.C bp in our experiments disagrees with published work in which A.T. -G.C transitions were reported to be the most frequent Taq-polymerase errors (10, 11, 12, 13) . Differences in the amplification conditions may be responsible for these discrepancies; e.g. high ratios of concentrations of Mg2+/total dNTPs in several published reports relative to a ratio of 1.7 in the present work; the use of relatively high concentrations of DMSO in our work in contrast to previous authors etc.. It should be stressed that our data does not allow it to calculate absolute error-frequencies for Taq-polymerase because the amount of residual, unrestricted wt-sequence in the amplification mixture cannot be assessed by the RFLP/PCR protocol.
In conclusion, the RFLP/PCR protocol described here allows the analysis of point mutations (bp-changes, small deletions and insertions) in any gene of known sequence without the need to select mutated cells on the basis of an altered phenotype. The method is highly sensitive and relatively simple but limited to mutations which result in the elimination of a restriction site. The experimental design of the RFLP/PCR approach to genotypic mutation analysis has been discussed previously (14, 15) .
